Abstracts tagged "corticosteroids"

Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium
Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Angela Chun¹, Lutfiyya Muhammad ² and Deirdre De Ranieri ³, ¹Lurie Children's Hospital, Chicago, Iowa, ²Northwestern University Feinberg School of Medicine, Chicago, ³Lurie Children's Hospital, Chicago, Illinois
Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium
Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis
Rana Masoud¹, Wajiha Jeelani ², Barbine Agbor Agbor ³, Teresa Hennon ², Brian Wrotniak ⁴ and Rabheh Abdul Aziz ², ¹Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, New York, ²Department of Pediatric Rheumatology, University at Buffalo, Oishei Children's Hospital, Buffalo, ³Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, ⁴Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, NY, USA, Buffalo
Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…
Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium
The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries
Mary Beth Son¹, Yukiko Kimura ², Kristiina Aalto ³, Lillemor Berntson ⁴, Johnathan Dallas ¹, Ciaran Duffy ⁵, Mia Glerup ⁶, Jaime Guzman ⁷, Troels Herlin ⁸, Petteri Hovi ⁹, Kimme Hyrich ¹⁰, Jens Klotsche ¹¹, Bo Magnusson ¹², Vanessa McIntyre ¹³, Ellen Nordal ¹⁴, Seza Ozen ¹⁵, Maria Jose Santos ¹⁶, Betul Sozeri ¹⁷ and Timothy Beukelman ¹⁸, ¹Boston Children's Hospital, Boston, Massachusetts, ²Hackensack Meridian School of Medicine, Hackensack, ³Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁴Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ⁵Ottawa, Canada, ⁶Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁷University of British Columbia and BC Children's Hospital, Vancouver, Canada, ⁸Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰Manchester, United Kingdom, ¹¹Berlin, Germany, ¹²Karolinska University Hospital, Stockholm, Sweden, ¹³Manchester University, Manchester UK, United Kingdom, ¹⁴Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ¹⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, ¹⁶Portugal, ¹⁷Boston, Turkey, ¹⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…
Abstract Number: 119 • 2020 Pediatric Rheumatology Symposium
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
Takayuki Kishi¹, Takako Miyamae ², Ryoko Sakai ³, Yumi Tani ², Satoru Nagata ¹ and Masayoshi Harigai ³, ¹Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ²Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Background: Immunosuppressive therapy is the mainstay of treatment of child systemic lupus erythematosus (cSLE). However until very recently, the treatment of cSLE lacked uniformity.…
Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium
Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Erin Balay¹, Jennifer Weiss ², Y. Ingrid Goh ³, Nathan Rubin ⁴ and Danielle Bullock ⁴, ¹University of Minnesota, saint paul, ²Hackensack University Medical Center, Hackensack, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Minnesota, Minneapolis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
Abstract Number: 273 • 2019 ACR/ARP Annual Meeting
Bone Health in Lupus: Findings from the Southern California Lupus Registry
Vaneet Sandhu, MBBS¹ and Sara Johnson ², ¹Loma Linda University, Loma Linda, CA, ²St George's University, Loma Linda, CA
Background/Purpose: The association of vitamin D deficiency with SLE is well established. While disease activity can itself cause pathologic bone remodeling and reduced vitamin D,…
Abstract Number: 858 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE
Saira Sheikh¹, Morton Scheinberg ², Cheng-Chung Wei ³, Dana Tegzova ⁴, William Stohl ⁵, Ricardo Acayaba de Toledo ⁶, Tamara Mucenic ⁷, Mauricio Abello Banfi ⁸, Kathleen Maksimowicz-McKinnon ⁹, Carlos Abud-Mendoza ¹⁰, Sandra Navarra ¹¹, Mercedes Garcia ¹², Ignacio Garcia-De La Torre ¹³, Josep Ordi Ros ¹⁴, Roger Abramino Levy ¹⁵, Damon L Bass ¹⁵, Jorge Ross Terrés ¹⁶, Raj Punwaney ¹⁶, Julia Harris ¹⁷, Alireza Nami ¹⁸, Amy Pierce ¹⁹, Kevin Thorneloe ²⁰, Beulah Ji ¹⁷ and David Roth ¹⁶, ¹University of North Carolina, Chapel Hill, NC, ²Centro de Pesquisas Clinicas do Hospital Abreu Sodré, São Paulo, Brazil, ³Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁴Institute of Rheumatology, Prague, Czech Republic, ⁵University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil, ⁷Hospital Moinhos Angeles de Vento, Porto Alegre, Brazil, ⁸Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁹Henry Ford Hospital, Wayne State University, Detroit, MI, ¹⁰Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatologia y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²Hospital San Martín, La Plata, Argentina, ¹³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Jalisco, Mexico, ¹⁴Hospital Vall d'Hebron, Barcelona, Spain, ¹⁵GlaxoSmithKline, Collegeville, PA, ¹⁶GSK, Collegeville, PA, ¹⁷GSK, Uxbridge, Middlesex, United Kingdom, ¹⁸Joint Muscle Medical Care and Research Institute, Charlotte, NC, ¹⁹ViiV Healthcare, Research Triangle Park, NC, ²⁰GSK, Collegeville, NC
Background/Purpose: Belimumab (BEL), approved in active, autoantibody-positive SLE, has demonstrated a positive efficacy/safety profile while suggesting potential for steroid sparing and reduced organ damage accrual.…
Abstract Number: 1309 • 2019 ACR/ARP Annual Meeting
Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis
Philip G Conaghan¹, Edgar Ross ², Alan Kivitz ³, Dennis Turk ⁴, Andrew Spitzer ⁵, Deryk Jones ⁶, Ryan Lanier ⁷, Amy Cinar ⁸, Joelle Lufkin ⁸ and Scott Kelley ⁸, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Brigham and Women's Hospital, Boston, MA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴University of Washington, Seattle, ⁵Cedars-Sinai Medical Center, Los Angeles, ⁶Ochsner Sports Medicine Institute, Harahan, GA, ⁷Analgesic Solutions, Natick, ⁸Flexion Therapeutics, Burlington
Background/Purpose: In a Phase 3 randomized controlled study, differing efficacy results were observed when triamcinolone acetonide extended-release (TA-ER) was compared to conventional TA crystalline suspension…
Abstract Number: 2068 • 2019 ACR/ARP Annual Meeting
Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications
Vivian Bykerk¹, Andrew Blauvelt ², Jeffrey Curtis ³, Cécile Gaujoux-Viala ⁴, Tore K. Kvien ⁵, William J. Sandborn ⁶, Kevin Winthrop ⁷, Christina Popova ⁸ and Xavier Mariette ⁹, ¹Hospital for Special Surgery, New York City, NY, ²Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Nîmes University Hospital, Nîmes, France, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶University of California, La Jolla, CA, ⁷Oregon Health and Science University, Portland, OR, ⁸UCB Pharma, Brussels, Belgium, ⁹Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: Certolizumab pegol (CZP) is an anti-TNF drug approved for rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD).…
Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Daisuke Kobayashi¹, Sayuri Takamura ², Yoko Wada ³, Takeshi Kuroda ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, ³Niigata Rinko Hospital, Niigata, Niigata, Japan, ⁴Health administration office, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Melissa E. Munroe¹, Carla J. Guthridge ¹, Sarah Kleckner ¹, Ly Tran ², Joel Guthridge ³, Debra J. Zack ⁴, Judith James ³ and Joan T. Merrill ⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Xencor, Inc., San Diego, CA, ⁵Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…
Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Magali Pacanowski Fournier¹, Antoine Brezin², Christophe Chiquet Sr.³, David Saadoun⁴, Jeremie Sellam⁵, Patrice Cacoub⁶, Pascal Sève⁷, Bahram Bodaghi Sr.⁸ and Laurent Kodjikian Sr.^9,10,11, ¹medical department, Magali Pacanowski Fournier is employee of AbbVie and own AbbVie stock, Rungis, France, ²Ophtalmology, Referral Center for Rare Ophthalmological Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, ophtalmology, France, Paris, France, ³ophtalmology, CHU-Grenoble-Alpes, La Tronche, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁷Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁸ophtalmology, Hôpital La Pitié-Salpêtrière; Université Sorbonne, paris, France, ⁹ophtalmology, Chu de La Croix-Rousse, hospices civils de Lyon, Lyon, France, ¹⁰université Claude Bernard lyon 1, villeurbanne, France, ¹¹UMR-CNRS 5510 Matéis, villeurbanne, France
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…
Abstract Number: 2191 • 2018 ACR/ARHP Annual Meeting
Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
Suzan Jaradat¹, Maheswari Muruganandam², Noelle Rolle², Wilmer Sibbitt Jr.³, William Hayward⁴, N. Suzanne Emil³, Monthida Fangtham³, Roderick Fields³ and Arthur Bankhurst³, ¹Internal Medicine, University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, ²University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, ³Rheumatology, University of New Mexico Health Sciences Center, Albuquerque, NM, ⁴The Department of Exercise and Sport Sciences, New Mexico Highlands University, Las Vegas, NM
Background/Purpose: Ultrasound (US)-guided injections in musculoskeletal medicine typically utilize either local puncture site sterility or conventional surgical sterility. We report on the safety and complications…
Abstract Number: 2198 • 2018 ACR/ARHP Annual Meeting
Evaluation of 18F-Fluorodeoxyglucose PET-CT Score at Baseline on the Therapeutic Response to Prednisone in Polymyalgia Rheumatica: A Retrospective Study
Nicolas Giraud¹, Maxime Sondag², Aline Charpentier², Hatem Boulahdour³, Clément Prati^4,5, Daniel Wendling^6,7 and Frank Verhoeven⁸, ¹Rheumatology, CHU de Besançon, Besançon, France, ²rheumatology, CHU de Besançon, Besancon, France, ³CHU de Besançon, Besançon, France, ⁴EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche Comté, Besancon, France, ⁵Rheumatology, University Hospital - Bourgogne Franche Comté University, Besancon, France, ⁶Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁷EA 4266, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France, F-25000 Besançon, France, ⁸EA 4267 PEPITE, Université de Bourgogne Franche Comté, Besançon, France
Background/Purpose: To evaluate the impact of 18F-fluorodeoxyglucose PET-CT (FDG-PET/CT) score at baseline, on the therapeutic response to prednisone, in patients with polymyalgia rheumatica (PMR). Methods:…
Abstract Number: 2390 • 2018 ACR/ARHP Annual Meeting
Incidence of and Risk Factors for Adrenal Suppression Following Ultrasound-Guided Intra-Articular Corticosteroid Injection with Triamcinolone Acetonide in Juvenile Idiopathic Arthritis
Katherine K Ngo¹, Angelina Bernier¹, Melissa E Elder², Renee F Modica² and Akaluck Thatayatikom¹, ¹Pediatrics, University of Florida, Gainesville, FL, ²Department of Pediatrics, University of Florida, Gainesville, FL
Background/Purpose: Intra-articular corticosteroid injection (IACI) is routinely used in juvenile idiopathic arthritis (JIA) with oligoarticular disease and as adjunct therapy for other types of JIA.…

1
2
3
…
6
Next Page »